Design Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 3, 2026

DSGN$10.21+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and par value data)

	June 30,	December 31,
	2026	2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$12,907	$16,856
Investment securities	194,489	202,989
Prepaid expenses and other current assets	4,617	3,939
Total current assets	212,013	223,784
Property and equipment, net	694	981
Right-of-use asset	2,422	1,438
Total assets	$215,129	$226,203
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$3,141	$2,312
Accrued expenses and other current liabilities (including related party amounts of $890 as of December 31, 2025)	8,099	10,743
Total current liabilities	11,240	13,055
Operating lease liability	2,031	645
Total liabilities	13,271	13,700
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2026 and December 31, 2025; 62,580,096 and 60,398,051 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	6	6
Additional paid-in capital	537,430	509,100
Accumulated deficit	(334,807)	(297,006)
Accumulated other comprehensive (loss) income	(771)	403
Total stockholders’ equity	201,858	212,503
Total liabilities and stockholders’ equity	$215,129	$226,203

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.